Blinatumomab Bridge Therapy for Mitigating Chemotoxicity in Children with Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children, and treatment-related toxicity remains high, especially for high-risk patients. Blinatumomab is the bispecific T-cell engager recently approved for relapsed/refractory ALL. Blinatumomab has a non-myelotoxic toxicity profile and causes B-cell depletion. Data on the use of blinatumomab in chemotherapy-induced toxicity is unclear. We report two pediatric patients with pre-B ALL, treated with blinatumomab because of chemotherapy-associated toxicity, with recovery and successful bridging to further chemotherapy. Blinatumomab can be considered in pediatric ALL patients who develop chemotherapy toxicity and whose treatment is delayed.